Nycomed gains EU marketing approval for osteoporosis product  

2006.05.03
Nycomed, headquartered near Copenhagen, and its US collaborator NPS Pharmaceuticals Inc., have received EU marketing authorisation of Preotact, a product for the treatment of osteoporosis

Nycomed, a pharmaceutical company headquartered near Copenhagen, and its US collaborator NPS Pharmaceuticals Inc., have received EU marketing authorisation of Preotact, a product for the treatment of osteoporosis. Preotact is a full-length parathyroid hormone developed to stimulate the growth of structurally normal bone lost because of osteoporosis.

The marketing authorisation includes the indication "treatment of osteoporosis in postmenopausal women at high risk of fractures". It is estimated that in Europe alone, 20 million women suffer from osteoporosis, a figure expected to increase. Håkan Björklund, Nycomed CEO says: "The EU approval strengthens our position as an attractive in-licensing partner and demonstrates our commitment to build a strong hospital and specialist product portfolio in Europe". Nycomed plans a European launch of Preotact in H2 this year.

Nycomed employs 3,300 people in Europe and Russia-CIS. The company is owned by capital funds with Nordic Capital as the main shareholder. In 2005, Nycomed generated revenues of DKK 5.6 bn (USD 952 m) and pre-tax profits of DKK 1.2 bn (USD 204 m). The news was reported by Ritzau and on Nycomed's website.

Link > Nycomed 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×